835 Epidemiological and clinicopathological characteristics of arsenic-related bladder cancer: A comparison between affected populations from contaminated and reference sites

The aim of this study was to investigate the impacts of radiation therapy (RT) on the occurrence risk of secondary bladder cancer (SBC) and on the patients’ survival outcome after being diagnosed with gynecological cancer (EC). The data was obtained from the SEER database between 1973 and 2015. Chi-squared test was used to compare the clinicopathological characteristics among the different groups. Fine and Gray’s competing risk model was used to assess the cumulative incidence and occurrence risk of SBC in GC survivors. Kaplan-Meier method was utilized for survival analysis. A total of 123,476 GC patients were included, among which 31,847 (25.8%) patients received RT while 91629 (74.2%) patients did not. The cumulative incidence of SBC was 1.59% or 0.73% among patients who had received prior GC specific RT or not, respectively. All EBRT (standardized incidence ratio (SIR) =2.49, 95% CI [2.17-2.86]), brachytherapy (SIR =1.96, 95% CI [1.60-2.38]), and combinational RT modality groups (SIR =2.73, 95% CI [2.24-3.28]) had dramatically higher SBC incidence as compared to the US general population. Receiving EBRT (HR = 2.83, 95% CI [2.34–3.43]), brachytherapy (HR = 2.17, 95% CI [1.67–2.82]), and combinational RT modality (HR = 2.97, 95% CI [2.34–3.77]) were independent risk factors for SBC development. Survival detriment was observed in SBC patients who received RT after GC diagnosis, as compared to those who did not receive RT. In conclusion, patients who underwent RT after GC had an increased risk of developing bladder as a secondary primary cancer. A long-term surveillance for SBC occurrence is necessary for GC patients who have received prior RT.

Download Full-text

Fluid intake and clinicopathological characteristics of bladder cancer: The West Midlands Bladder Cancer Prognosis Programme (BCPP)

European Urology Supplements ◽

10.1016/s1569-9056(18)31904-3 ◽

2018 ◽

Vol 17 (2) ◽

pp. e1529-e1530

Author(s):

M. Van Hensbergen ◽

F.H.M. Van Osch ◽

S. Jochems ◽

N. James ◽

M. Wallace ◽

...

Keyword(s):

Bladder Cancer ◽

Fluid Intake ◽

Clinicopathological Characteristics ◽

Cancer Prognosis ◽

The West ◽

West Midlands

Download Full-text

Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer

Scientific Reports ◽

10.1038/s41598-021-93245-1 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Matias Blomqvist ◽

Ilmari Koskinen ◽

Eliisa Löyttyniemi ◽

Tuomas Mirtti ◽

Peter J. Boström ◽

...

Keyword(s):

Bladder Cancer ◽

Predictive Value ◽

Treatment Options ◽

Clinicopathological Characteristics ◽

Stem Cell Markers ◽

Cancer Specific Survival ◽

Specific Mortality ◽

Cancer Specific Mortality ◽

Resistance To Chemotherapy

AbstractTransurethral resection of bladder tumor (TUR-BT) and radical cystectomy (RC) are standard treatment options for bladder cancer (BC). Neoadjuvant chemotherapy (NAC) prior to RC improves outcome of some patients but currently there are no valid biomarkers to identify patients who benefit from NAC. Presence of cancer stem cells (CSC) has been associated with poor outcome and resistance to chemotherapy in various cancers. Here we studied the expression of stem cell markers ALDH1, SOX2 and SSEA-4 with immunohistochemistry in tissue microarray material consisting of 195 BC patients treated with RC and 74 patients treated with TUR-BT followed by NAC and RC. Post-operative follow-up data of up to 22 years was used. Negative to weak cytoplasmic SOX2 staining was associated with lymphovascular invasion and non-organ confined disease. It was also associated with shortened cancer-specific survival, but the finding was not statistically significant. Contrary to previous reports, none of the other tested biomarkers were associated with cancer-specific mortality or clinicopathological characteristics. Neither were they associated with response to NAC. Despite the promising results of previously published studies, our results suggest that CSC markers ALDH1, SOX2 and SSEA-4 have little if any prognostic or predictive value in BC treated with RC.

Download Full-text

Impact of age and gender on the clinicopathological characteristics of bladder cancer

Indian Journal of Urology ◽

10.4103/0970-1591.52916 ◽

2009 ◽

Vol 25 (2) ◽

pp. 207 ◽

Cited By ~ 21

Author(s):

Anil Mandhani ◽

Parag Gupta ◽

Manoj Jain ◽

Rakesh Kapoor ◽

K Muruganandham ◽

...

Keyword(s):

Bladder Cancer ◽

Clinicopathological Characteristics ◽

Age And Gender ◽

And Gender

Download Full-text

Squamous Differentiation in pT1 Low-Grade Bladder Urothelial Carcinoma is Associated with High Risk of Recurrence

10.21203/rs.3.rs-378427/v1 ◽

2021 ◽

Author(s):

Wanqing Wei ◽

Jianwei Zhang ◽

Keruo Wang ◽

Shunlin Xia ◽

Zhiqun Shang ◽

...

Keyword(s):

Bladder Cancer ◽

Independent Predictor ◽

Hazard Analysis ◽

Postoperative Recurrence ◽

Clinicopathological Characteristics ◽

Low Grade ◽

Squamous Differentiation ◽

Kaplan Meier ◽

Bladder Urothelial Carcinoma ◽

Multiple Recurrences

Abstract Background A large number of studies have confirmed that squamous differentiation is closely related to the prognosis of bladder cancer, and studies also showed that it is an independent predictor for the prognosis of such disease. However, the role of squamous differentiation in pT1 low-grade bladder cancer (LGBC) has not been reported yet. This study mainly intends to explore the clinical significance of squamous differentiation in pT1 LGBC.Methods The clinicopathological data of 582 patients with pT1 LGBC from April 2007 to December 2018 were retrospectively analyzed, including 51 cases pathologically diagnosed as pT1 LGBC with squamous differentiation, and 531 cases as pT1 LGBC without squamous differentiation. The clinicopathological characteristics and prognosis of patients in the two groups were compared.Results 51 cases (8.7%) were pathologically diagnosed as pT1 LGBC with squamous differentiation. As compared with non-squamous differentiation, squamous differentiation was closely related to the age of patients (P=0.009) and postoperative recurrence (P<0.001). Further studies on the pT1 LGBC recurrence group showed that the patients in the squamous differentiation group were more prone to multiple recurrences (P=0.033) and invasive recurrence (P<0.001) after surgery. The Kaplan-Meier analysis indicated that pT1 LGBC patients with squamous differentiation had shorter recurrence-free survival (RFS) time. The Cox proportional hazard analysis confirmed that squamous differentiation was an independent predictor of RFS time in patients with pT1 LGBC.Conclusions Squamous differentiation is closely related to postoperative recurrence of pT1 LGBC, especially multiple recurrences and invasive recurrence after surgery. Squamous differentiation is an independent predictor of the RFS time in patients with pT1 LGBC.

Download Full-text

Rac3 Expression and its Clinicopathological Significance in Patients With Bladder Cancer

Pathology & Oncology Research ◽

10.3389/pore.2021.598460 ◽

2021 ◽

Vol 27 ◽

Author(s):

Mei Chen ◽

Zhenyu Nie ◽

Hui Cao ◽

Yuanhui Gao ◽

Xiaohong Wen ◽

...

Keyword(s):

Bladder Cancer ◽

Western Blot ◽

Enrichment Analysis ◽

Clinicopathological Characteristics ◽

Gene Set Enrichment Analysis ◽

The Cancer Genome Atlas ◽

Qrt Pcr ◽

P53 Signaling ◽

Kaplan Meier ◽

Normal Bladder

Background: Ras-related C3 botulinum toxin substrate 3 (Rac3) is overexpressed in malignancies and promotes tumor progression. However, the correlations between Rac3 expression and the clinicopathological characteristics and prognoses of patients with bladder cancer (BC) remain unclear.Methods: Data from The Cancer Genome Atlas (TCGA) were used to analyze Rac3 expression in BC and normal bladder tissues and validated using the Oncomine database, quantitative real-time PCR (qRT-PCR) and western blot. The Kaplan-Meier method was used to analyze the relationship between Rac3 expression and the prognosis of patients with BC. Cox univariate and multivariate analyses of BC patients overall survival (OS) were performed. Signaling pathways that potentially mediate Rac3 activity in BC were then analyzed by gene set enrichment analysis (GSEA).Results: The Rac3 expression in BC tissues was significantly higher than that in normal bladder tissues. Rac3 expression was significantly correlated with grade and stage. Overexpression of Rac3 was associated with a poor prognosis. GSEA showed that the cell cycle, DNA replication, p53 signaling pathway and mismatch repair were differentially enriched in the high Rac3 expression phenotype. The qRT-PCR and western blot results confirmed that the Rac3 expression in BC tissues was higher than that in normal bladder tissues.Conclusion: Rac3 is highly expressed in BC, which is related to the advanced clinicopathological variables and adverse prognosis of patients with BC. These results provide a new therapeutic target for BC.

Download Full-text

Clinicopathological features of lipid cell variant of urothelial carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.6_suppl.487 ◽

2018 ◽

Vol 36 (6_suppl) ◽

pp. 487-487

Author(s):

Tatsuro Hayashi ◽

Go Kimura ◽

Keigo Takahashi ◽

Keita Shibayama ◽

Kotaro Obayashi ◽

...

Keyword(s):

Bladder Cancer ◽

Lymph Node ◽

Urothelial Carcinoma ◽

Cancer Patients ◽

Distant Metastasis ◽

Disease Free Survival ◽

Clinicopathological Characteristics ◽

High Grade ◽

Small Series ◽

Cell Variant

487 Background: Lipid cell variant (LCV) of urothelial carcinoma (UC) which was first described by Mostofi et al in 1999 is a very rare variant of UC. Because it has only been documented in occasional case reports and a small series about this variant since then, clinicopathological characteristics of LCV are not yet clarified. In this study, we assessed the clinicopathological characteristics of LCV experienced in our hospital. Methods: The medical records of patients with LCV, who were treated in our hospital between September 2015 and September 2017, were retrospectively reviewed and analyzed. Results: In this period, of 301 patients undergoing TURBT and 42 patients undergoing nephroureterectomy, 13 patients including 10 patients with bladder cancer and 3 with pelvic ureter cancer, were found to be diagnosed as LCV of UC at our hospital. The median observation period of these patients was 6 months (IQR, 4-9 months). Among 10 bladder cancer patients who had confirmed this variant in transurethral resection of bladder tumor (TURBT) specimens, all cases had concurrent high-grade UC and the most cases had tumor features including pT2 or more local stages and lympho-vascular invasion (LVI) positive. Co-existence of micropapillary and/or plasmacytoid variant were seen in 5 patients. Lymph node metastases were observed in 3 patients, and this variant was histologically confirmed within the lymph node metastatic tissue in one case. No patient had distant metastasis. Among 3 pelvic ureter cancer patients who had undergone nephroureterectomy, all cases had concurrent high-grade UC and the most cases had tumor features including pT3 local stage and LVI positive. Micropapillary variant was coexisted in one patient. No patient had distant metastasis. 7 patients were no evidence of disease and 6 were alive with disease. The estimated median time from surgery to recurrence was not reached. The 6-months disease-free survival rate was 59%. Conclusions: LCV is seen in the patients who have high-grade UC, and tends to be accompanied with other aggressive variants including micropapillary and plasmacytoid. All patients with this variant had advanced stage cancer at presentation with high recurrence rates.

Download Full-text

Expression and Clinical Significance of MMP-28 in Bladder Cancer

Technology in Cancer Research & Treatment ◽

10.1177/1533033820974017 ◽

2020 ◽

Vol 19 ◽

pp. 153303382097401

Author(s):

Heng Wang ◽

Jun-xiu Wu ◽

Xin-Peng Chen ◽

Qi Zhang ◽

Hai-bin Wei ◽

...

Keyword(s):

Bladder Cancer ◽

Urothelial Carcinoma ◽

Cancer Progression ◽

Bladder Carcinoma ◽

Clinicopathological Characteristics ◽

Urinary Bladder Carcinoma ◽

Normal Bladder ◽

Patient Prognosis ◽

High Level ◽

Risk Of Cancer

Aims: The aim of this study to determine the expression of MMP-28 in bladder urothelial carcinoma and to analyze the correlation between MMP-28 and the clinicopathological characteristics of human bladder carcinoma, and its relationship with patient prognosis. Methods: A total of 491 surgically resected bladder cancer samples and 80 normal tissue adjacent to the tumor were stained by immunohistochemistry. The expression of MMP-28 in these samples was quantitated, and the value of MMP-28 as a marker of bladder cancer and prognosis was assessed. Results: The expression of MMP-28 in urinary bladder carcinoma was higher than in normal bladder mucosa. The high level of MMP-28 was significantly correlated with tumor histology grade, lymphatic metastasis, lymph node infiltration, and distant metastasis (P < 0.05). The upregulation of MMP-28 was also closely related to the risk of cancer progression and the survival of patients. Further analysis documented that high expression of MMP-28 was associated with decreased overall survival in bladder cancer patients. Conclusions: The abnormal expression of MMP-28 may be related to the initiation and development of urothelial carcinoma. The upregulation of MMP-28 can be used as one of the effective indicators to diagnose bladder cancer and predict tumor progression.

Download Full-text

Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer

Biomarker Research ◽

10.1186/s40364-020-00232-1 ◽

2020 ◽

Vol 8 (1) ◽

Author(s):

Nina Andersson ◽

Johan Ohlsson ◽

Sara Wahlin ◽

Björn Nodin ◽

Karolina Boman ◽

...

Keyword(s):

Bladder Cancer ◽

Neoadjuvant Chemotherapy ◽

Population Based ◽

Clinicopathological Characteristics ◽

Low Grade ◽

Urothelial Bladder Cancer ◽

Squamous Differentiation ◽

Lymphocyte Antigen ◽

Urothelial Bladder ◽

Incident Cases

Abstract Background Screening across a multitude of normal and malignant tissues revealed an enhanced expression of lymphocyte antigen 6 superfamily member D (LY6D) in squamous epithelium and urothelium, as well as in malignancies derived therefrom. The aim of this study was to further delineate the protein expression of LY6D in urothelial bladder cancer, with particular attention to its relationship with clinicopathological characteristics and patient outcome. Methods Immunohistochemical expression of LY6D was assessed in tissue microarrays with urothelial bladder cancer tumours from three independent patient cohorts; one with transurethral resection of the bladder (TURB) specimens of mixed tumour stages from 110 consecutive cases, one with tumours of mixed stages from 260 incident cases in a population-based cohort, and one with paired TURB specimens, resected tumours and a subset of lymph node metastases from 145 patients with muscle-invasive bladder cancer (MIBC). Chi-square and non-parametric tests were applied to examine associations of LY6D expression with clinicopathological characteristics. Kaplan-Meier and Cox regression analyses were applied to examine 5-year overall survival (OS) and recurrence free survival (RFS) in relation to LY6D expression. Results In the two cohorts with mixed stages, positive LY6D expression was denoted in 63 and 64% of the cases, respectively, and found to be significantly higher in low-grade and less invasive tumours. Negative LY6D expression was significantly associated with a reduced 5-year OS, although not independently of established prognostic factors. In the population-based cohort, LY6D expression was higher in tumours with squamous differentiation and lower in other variant histologies compared to pure urothelial tumours, and the association of LY6D expression with survival was somewhat enhanced after exclusion of the former. LY6D expression was generally lower in the MIBC cohort, and even more reduced in resected tumours compared to TURB specimens in patients who had not received neoadjuvant chemotherapy. There were no significant associations between LY6D expression and RFS, neither allover nor in relation to neoadjuvant chemotherapy. Conclusion LY6D is a marker of urothelial and squamous differentiation that may add useful diagnostic and prognostic information to better guide the clinical management of bladder cancer, given that the presence of variant histology is taken into account.

Download Full-text